Target identification for small-molecule discovery in the FOXO3a tumor-suppressor pathway using a biodiverse peptide library
- Cell Chem Biol. 2021 Nov 18;28(11):1602-1615.e9. doi: 10.1016/j.chembiol.2021.05.009.
- 1. Medical Research Council Cancer Unit, University of Cambridge, Hills Road, Cambridge CB2 0XZ, UK.
- 2. Telethon Kids Institute, Centre for Child Health Research, University of Western Australia & PYC Therapeutics Limited, Nedlands, WA 6009, Australia.
- 3. Center for Chemical Biology & Therapeutics, inStem & NCBS, Bellary Road, Bangalore 560065, India.
- 4. PhoreMost Ltd., Babraham Research Campus, Cambridge CB22 3AT, UK.
- 5. Medical Research Council Cancer Unit, University of Cambridge, Hills Road, Cambridge CB2 0XZ, UK; PhoreMost Ltd., Babraham Research Campus, Cambridge CB22 3AT, UK.
- 6. Medical Research Council Cancer Unit, University of Cambridge, Hills Road, Cambridge CB2 0XZ, UK; Center for Chemical Biology & Therapeutics, inStem & NCBS, Bellary Road, Bangalore 560065, India; PhoreMost Ltd., Babraham Research Campus, Cambridge CB22 3AT, UK. Electronic address: [email protected].
Genetic screening technologies to identify and validate macromolecular interactions (MMIs) essential for complex pathways remain an important unmet need for systems biology and therapeutics development. Here, we use a library of peptides from diverse prokaryal genomes to screen MMIs promoting the nuclear relocalization of Forkhead Box O3 (FOXO3a), a tumor suppressor more frequently inactivated by post-translational modification than mutation. A hit peptide engages the 14-3-3 family of signal regulators through a phosphorylation-dependent interaction, modulates FOXO3a-mediated transcription, and suppresses Cancer cell growth. In a crystal structure, the hit peptide occupies the phosphopeptide-binding groove of 14-3-3ε in a conformation distinct from its natural peptide substrates. A biophysical screen identifies drug-like small molecules that displace the hit peptide from 14-3-3ε, providing starting points for structure-guided development. Our findings exemplify "protein interference," an approach using evolutionarily diverse, natural peptides to rapidly identify, validate, and develop chemical probes against MMIs essential for complex cellular phenotypes.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Drug DerivativeResearch Areas: Cancer